HOWL - NASDAQ

Werewolf Therapeutics, Inc.

HOWL·NASDAQ

$1.04

-3.7%

HealthcareBiotechnology

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.48M

EPS-1.3200

P/E Ratio-0.48

Earnings Date05/07/2026

howl

Net Receivables

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Werewolf Therapeutics, Inc. Competitors Analysis of Net Receivables

HOWL · NASDAQ

Company	Net Receivables	CAGR 3Y	CAGR 5Y	CAGR 10Y
Werewolf Therapeutics, Inc. NASDAQ:HOWL	0.00	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	161.00K	199.4%	N/A	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	1490.93B	N/A	N/A	N/A
Cibus, Inc. NASDAQ:CBUS	703.00K	9.9%	N/A	16.2%
Immunic, Inc. NASDAQ:IMUX	4.12M	80.3%	13.9%	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	0.00	N/A	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	0.00	N/A	N/A	N/A
Vaxart, Inc. NASDAQ:VXRT	51.34M	157.5%	273.1%	56.0%
XBiotech Inc. NASDAQ:XBIT	360.00K	-27.3%	-47.4%	N/A
CEL-SCI Corporation AMEX:CVM	0.00	N/A	N/A	N/A
CervoMed Inc. NASDAQ:CRVO	2.25M	35.0%	N/A	N/A

Werewolf Therapeutics, Inc. Fair Value Envelope

HOWL · NASDAQ

Our analysis suggests that HOWL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.04, this represents a potential HIDDEN relative to our calculated worth for Werewolf Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.04

Related Guides

Blog Categories

Continue your HOWL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.